This story was up to date at 8:35 p.m.
April 23, 2021 — Use of the Johnson & Johnson COVID-19 vaccine ought to resume in the US for all adults, the FDA and CDC mentioned Friday, though well being care suppliers ought to warn sufferers of the chance of creating the uncommon and severe blood clots that brought on the businesses to pause the vaccine’s distribution earlier this month.
“What we’re seeing is the general fee of occasions was 1.9 circumstances per million folks. In girls 18 to 29 years there was an approximate 7 circumstances per million. The chance is even decrease in girls over the age of fifty at .9 circumstances per million,” CDC Director Rochelle Walensky, MD, mentioned in a information briefing Friday night..
In the long run, the potential advantages of the vaccine far outweighed its dangers.
“When it comes to advantages, we discovered that for each 1 million doses of this vaccine, the J&J vaccine might forestall over 650 hospitalizations and 12 deaths amongst girls ages 18-49,” Walensky mentioned. The potential advantages to girls over 50 have been even higher: It might forestall 4700 hospitalizations and 650 deaths.
“In the long run, this vaccine was proven to be protected and efficient for the overwhelming majority of individuals,” Walensky mentioned at a press briefing on Friday night time.
The advice to proceed the vaccine’s rollout got here barely 2 hours after a CDC Advisory Committee on Immunization Practices voted to suggest the pause be lifted. The vote was 10-4 with one abstention.
The choice additionally contains directions for the warning directed at girls below 50 who’ve an elevated danger of a uncommon however severe blood clot dysfunction referred to as thrombosis with thrombocytopenia syndrome (TTS).
As of April 21, 15 circumstances of TTS, all in girls and 13 of them in girls below 50, have been confirmed amongst 7.98 million doses of the J&J vaccine administered within the U.S. Three girls have died.
The FDA and CDC advisable the pause on April 13 after reviews that 6 girls developed a blood clotting dysfunction 6 to 13 days after they obtained the J&J vaccine.
William Schaffner, MD, an infectious illness knowledgeable at Vanderbilt College in Nashville, and a non-voting ACIP member, mentioned in an interview the panel made the correct advice.
He applauded each the choice to restart the vaccine and the up to date warning info that “will clarify [TTS] extra absolutely to folks, notably girls, who’re coming to be vaccinated.”
As to girls within the danger group needing to have a alternative of vaccines, Schaffner mentioned that can be addressed otherwise throughout the nation.
“Each supplier is not going to have different vaccines of their location so there can be many various methods to do that. You will have to get this info and choose which website you’re going to relying on which vaccine is on the market if this matter is essential to you,” he famous.
ACIP made right this moment’s resolution after a 6-hour emergency assembly to listen to proof on good thing about Johnson & Johnson’s protecting advantages in opposition to COVID-19 vs. danger of TTS.
Within the CDC-FDA press briefing, Walensky identified that over the previous few days, as regulators have reviewed the uncommon occasions, newly recognized sufferers had been handled appropriately, with out using heparin, which isn’t suggested for treating TTS.
In consequence, regulators felt like their messages had gotten out to docs who now knew learn how to take particular precautions when treating sufferers with the dysfunction.
She mentioned the Johnson & Johnson shot remained an essential choice as a result of it was handy to provide and simpler to retailer than the opposite vaccines at the moment approved within the U.S.
Peter Marks, MD, the director of FDA’s Heart for Biologics Analysis and Analysis, mentioned the company had already added info describing the chance of the uncommon clotting dysfunction to its truth sheets for sufferers and docs.
Janet Woodcock, appearing commissioner of the FDA, mentioned vaccination facilities might resume giving the “one and completed” photographs as early as tomorrow morning.